Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Risks and Uncertainties (Details Textual)

v3.24.2.u1
Note 2 - Risks and Uncertainties (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Retained Earnings (Accumulated Deficit), Total $ (125,828)       $ (125,828)   $ (115,558)  
Net Income (Loss) Attributable to Parent, Total (5,119) $ (5,151) $ (4,477) $ (5,272) (10,270) $ (9,749)    
Net Cash Provided by (Used in) Operating Activities, Total         (11,172) (10,119)    
Cash, Cash Equivalents, and Short-Term Investments, Total 54,100       54,100      
Working Capital 51,900       51,900      
Stockholders' Equity Attributable to Parent, Ending Balance 53,415 $ 46,349 $ 59,743 $ 27,022 53,415 $ 59,743 $ 51,057 $ 31,827
Proceeds from Issuance of Common Stock, Net         11,700      
DM199 Phase 2 Trial [Member]                
Research and Development Arrangement, Anticipated Cost $ 1,500       $ 1,500